These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7591548)

  • 1. Outcomes measurement. The key to the appropriate use of pharmaceuticals.
    Grey RR; Townsend RJ; Sanders CA
    Int J Technol Assess Health Care; 1995; 11(3):472-84. PubMed ID: 7591548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precipitating factors for pharmaceutical firms.
    McCarthy R
    State Health Care Am; 1997; ():39-43. PubMed ID: 10168083
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomics research credibility: a controversial and recurring theme in health outcomes research.
    Minshall ME; Kody MC; Mosbacher F
    Med Care; 1999 Apr; 37(4 Suppl Lilly):AS12-9. PubMed ID: 10217388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic outcomes and contemporary pharmacy practice.
    Reeder CE
    Am Pharm; 1993 Dec; NS33(12 Suppl):S3-6. PubMed ID: 8109541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Industry's efforts: devices and pharmaceuticals.
    Sanders CA
    Ann Thorac Surg; 1995 Nov; 60(5):1537-40. PubMed ID: 8526683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes research, PORTs, and health care reform.
    Wennberg JE; Barry MJ; Fowler FJ; Mulley A
    Ann N Y Acad Sci; 1993 Dec; 703():52-62. PubMed ID: 8192318
    [No Abstract]   [Full Text] [Related]  

  • 7. Widespread assessment of risk-adjusted outcomes: lessons from local initiatives.
    Iezzoni LI; Greenberg LG
    Jt Comm J Qual Improv; 1994 Jun; 20(6):305-16. PubMed ID: 8087195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research.
    Kozma CM; Reeder CE; Schulz RM
    Clin Ther; 1993; 15(6):1121-32; discussion 1120. PubMed ID: 8111809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The decision to conduct a head-to-head comparative trial: a game-theoretic analysis.
    Mansley EC; Elbasha EH; Teutsch SM; Berger ML
    Med Decis Making; 2007; 27(4):364-79. PubMed ID: 17761957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights from an outcomes researcher.
    Clancy CM
    Manag Care; 1997 Apr; 6(4):56-9. PubMed ID: 10167001
    [No Abstract]   [Full Text] [Related]  

  • 11. Health care reform and the pharmaceutical industry.
    Mossinghoff GJ
    Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision analysis: balancing quality and cost.
    Brasel KJ; Weigelt JA
    Infect Control Hosp Epidemiol; 1997 Feb; 18(2):146-8. PubMed ID: 9120246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the Agency for Health Care Policy and Research (AHCPR) in improving outcomes of care.
    McCormick KA; Cummings MA; Kovner C
    Nurs Clin North Am; 1997 Sep; 32(3):521-42. PubMed ID: 9254637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.
    Reeder CE
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S5-8. PubMed ID: 8846244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health outcomes analysis and its applications].
    Carrera-Hueso FJ
    Rev Med Univ Navarra; 1997; 41(4):237-44. PubMed ID: 10420964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological challenges and innovations in patient outcomes research.
    Maklan CW; Greene R; Cummings MA
    Med Care; 1994 Jul; 32(7 Suppl):JS13-21. PubMed ID: 8028410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-31. PubMed ID: 29361657
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of healthcare reform in the Netherlands.
    Rutten F
    Pharmacoeconomics; 2004; 22(2 Suppl 2):65-71. PubMed ID: 15660478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.